- |||||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), imipenem/relebactam / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Clinical, Review, Journal: Approach to the treatment of patients with serious multidrug-resistant Pseudomonas aeruginosa infections. (Pubmed Central) - Aug 11, 2021 Though these newer agents are promising options for the treatment of MDR-PSA, clinical data remain generally limited. Future studies are needed to determine optimal agents for the empiric and definitive treatment of MDR-PSA.
- |||||||||| Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Fetroja (cefiderocol) / Shionogi
Clinical, Journal: Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance. (Pubmed Central) - Jul 16, 2021 Our findings suggest that alterations in the target binding sites of P. aeruginosa-derived AmpC β-lactamases have the potential to reduce the activity of 3 of 4 novel β-lactams (ie, ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol) and potentially increase susceptibility to imipenem-relebactam. These findings are in need of validation in a larger cohort.
- |||||||||| imipenem/relebactam / Merck (MSD), Vabomere (meropenem/vaborbactam) / Melinta Therap, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
Journal: Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany. (Pubmed Central) - Jul 10, 2021 The emergence of the NDM-5 carbapenemase was evidenced in particular for the E. coli ST167 clone, which is a successful epidemic clone, known to be associated to both multi-resistance and virulence traits and is therefore of high public health concern. The occurrence of clonally related NDM-5-producing E. coli isolates in Switzerland and Germany further indicates the international spread of this multidrug-resistant superbug at least throughout Europe.
- |||||||||| Journal: Role of new antibiotics for KPC-producing Klebsiella pneumoniae. (Pubmed Central) - Jul 4, 2021
These modified agents from old antibiotic classes illustrate the challenges of this requirement to address class-specific resistance mechanisms while critical gaps and some cross-resistance within a class, or to unrelated antibiotic classes, remain. The diverse molecular mechanisms and increasing diversification of carbapenem resistance among Klebsiella isolates requires improved rapid molecular diagnostic capabilities and stringent stewardship programmes to preserve the efficacy of new antibiotics for as long as possible.
- |||||||||| Review, Journal: Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections. (Pubmed Central) - Jul 4, 2021
Emerging treatment options for Gram-negative bacilli we considered comprise ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, aztreonam-avibactam, minocycline, fosfomycin, eravacycline, plazomicin, and cefiderocol...Knowledge of mechanisms of action and resistance patterns allows physicians to increasingly drive antimicrobial treatment towards a precision medicine approach. Strict adherence to antimicrobial stewardship practices will allow us to preserve the emerging antimicrobials for our future.
- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. (Pubmed Central) - Jul 2, 2021 Relebactam did potentiate imipenem against ESBL-producing P. aeruginosa, which are mostly imipenem resistant via OprD loss, but this potentiation was generally insufficient to reduce imipenem MICs to the clinical range. Imipenem resistance owing to KPC carbapenemases was reversed by relebactam in P. aeruginosa, just as for Enterobacterales.
- |||||||||| cefepime/zidebactam IV (WCK 5222) / Wockhardt
Preclinical, Journal: In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems. (Pubmed Central) - Jun 22, 2021 The activity of cefepime-zidebactam against carbapenem-resistant Gram-negatives is ascribed to its β-lactam enhancer mechanism of action (i.e., zidebactam binding to PBP2 and its universal stability to both serine β-lactamases and MBLs). The results from this study support the continued development of cefepime-zidebactam as a potential therapy for infections caused by Enterobacterales, P. aeruginosa, and other non-fermentative Gram-negative bacilli where resistance to marketed antimicrobial agents is a limiting factor.
- |||||||||| Clinical, PK/PD data, Journal: Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors. (Pubmed Central) - Jun 22, 2021
Suboptimal clinical response rate with ceftazidime-avibactam and ceftolozane-tazobactam was reported in phase II-III trials in patients with moderate kidney injury; data on patients undergoing renal replacement therapy are limited to some case reports; dose adjustment in augmented renal clearance is provided only for cefiderocol. Implementation of altered dosing strategies (prolonged infusion and/or higher dosage) coupled with adaptive real-time therapeutic drug monitoring could represent the most effective approach in warranting optimal pharmacokinetic/pharmacodynamic targets with novel BLs and/or BL/BLIs in challenging scenarios, thus minimizing the risk of clinical failure and/or of resistance selection.
- |||||||||| imipenem/relebactam / Merck (MSD)
Journal: Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam. (Pubmed Central) - Apr 22, 2021 Given their high in vitro susceptibility, Enterobacteriaceae infections in China should be considered for IMI/REL treatment, especially with isolates that are not susceptible to carbapenems. The biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required.
- |||||||||| Review, Journal: An Update on Eight "New" Antibiotics against Multidrug-Resistant Gram-Negative Bacteria. (Pubmed Central) - Apr 7, 2021
All of these new antibiotics are active against ESBL, and almost all of them are active against CPE caused by KPC beta-lactamase, but only some of them are active against CPE due to MBL or OXA beta-lactamases. At present, all of these new antibiotics are approved by the U.S. Food and Drug Administration for cUTI (except eravacycline) and most of them for cIAI (eravacycline, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam) and for HAP or VAP (cefiderocol, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam).
|